1. Body mass, BMI, plasma lipids, lipoproteins, and glucose homeostasis at baseline, and following placebo and rosuvastatin periods
Dmitri Sviridov et al. Atherosclerosis 2007

2. Parameters of reverse cholesterol transport following placebo and rosuvastatin periods
Dmitri Sviridov et al. Atherosclerosis 2007

3. Significant associations between plasma lipoproteins and cholesterol efflux after placebo and rosuvastatin treatment
Dmitri Sviridov et al. Atherosclerosis 2007

4. Ratios of the cholesterol efflux values between placebo versus active treatment periods
values with whole plasma incubations
values following precipitation of apoB lipoproteins
Ratios of the cholesterol efflux values between placebo versus active treatment periods shown as the changes from an arbitrary unity value. Panel A shows values with whole plasma incubations and Panel B shows the values following precipitation of apoB lipoproteins. The mean values of the arbitrary units are 7.1% with whole plasma (Panel A) and 3.9% with apoB depleted plasmas (Panel B). The values describe cholesterol released from cells to 2% plasma during 2 h incubations.
Dmitri Sviridov et al. Atherosclerosis 2007

5. Relationships between percent cholesterol efflux and plasma concentrations of LDL-C, HDL-C and LpA-I during placebo period
Dmitri Sviridov et al. Atherosclerosis 2007